NEW YORK (GenomeWeb News) – GnuBio announced today it obtained a worldwide license to microfluidics- and emulsion-based methods for nucleic acid analysis.
The technology, which was licensed from the laboratory of David Weitz, one of the founders of GnuBio, will be used by the startup firm to develop its DNA sequencer.
Weitz is a professor of physics and applied physics at Harvard University.
GnuBio is developing a scalable microfluidics-based sequencer where reactions take place in picoliter-sized drops. The goal is to sequence the human genome at 30x coverage at less than $100.
The platform would also have the capability to run diagnostic scale batches across a small candidate gene region at 100x coverage for less than $2 per sample, the company said in a statement
Terms of the deal were not disclosed.